logo
Why It's Difficult For People With Chronic Pain To Gain Their Doctor's Trust

Why It's Difficult For People With Chronic Pain To Gain Their Doctor's Trust

Forbes08-05-2025

RÜCKENSCHMERZEN sind zu einer der weitverbreitetste Krankheit geworden. Oft laufen die Betroffenen ... More jahrelang von einem Arzt zum nächsten, ohne daß ihr Leiden gelindert werden kann. Dabei wird häufig übersehen, daß Rückenschmerzen auch psychisch bedingt sein können. aka. Rückenschmerzen / Überschrift: WDR SERVICEZEIT GESUNDHEIT. (Photo by kpa/United Archives via Getty Images)
Many people with chronic pain find themselves interacting with clinicians who do not seem to trust them. Why is it hard to establish a trusting relationship with your doctor? And what can you do about it?
I have been on both sides of the exam table – as a physician caring for people with chronic pain and as a patient slowly coming to realize he is struggling with chronic pain. I would like to share a story I hope will help you understand why it can be difficult to gain the trust of your physicians.
It was the early 90s, and I was splitting time between two primary care clinics. One Tuesday, I took care of a man in his mid-30s who had previously sustained a serious back injury, with X-rays showing significant damage to multiple lumbar vertebrae. He told me that he experienced a flare of his lower back that morning after picking something up. The pain was now so bad that I had to help him get on the exam table. After assuring myself he had not suffered any nerve damage, I prescribed him a modest supply of oxycodone. (Remember it was the 90s—that's what we did!)
Two days later, I was working in the other clinic and saw the same man in the waiting room, scheduled to see one of my colleagues. I told the colleague that I was familiar with the patient he was about to see and asked my colleague to reach out to me after he finished examining him. The patient told my colleague that he had tweaked his back 'just that morning.' My colleague was inclined to prescribe him narcotics, but I told him about the Tuesday appointment, and we got to digging around for more information. After a few calls, we discovered that this patient was notorious for rotating across clinics seeking narcotics.
In retrospect, I can see all kinds of things I did wrong that week. I gave out narcotics too freely to a patient I barely knew. When I discovered his deception, I did not call an addiction expert to see if we could help this man overcome his need for narcotics. Instead, my colleague and I confronted him about his deceptive behavior and sent him home without further treatment.
But I am not telling you this story to reflect on my mistakes. Instead, I want to share my feelings.
I felt betrayed. I was trying to help this man, earnestly assessing his situation and prescribing a treatment I thought would alleviate his pain. I felt embarrassed that he had so easily fooled me. The dude knew all the right things to say, all the right 'pain postures' to pose in to convince me to prescribe the medications he desired. And I felt angry. I tried to help him and he showed his gratitude by lying to me.
Flooded with emotions, I lost the ability to feel compassion for whatever issues were causing this man to spend his time in medical waiting rooms seeking narcotics.
More importantly, I became more suspicious of subsequent patients who came to clinic complaining of pain. How do I know they are telling me the truth? Their x-rays look horrendous but how do I know whether they are feeling pain? That wince they display when I raise their leg in the air – how do I know that's not an act?
I am telling you this story because someday you may tell a physician about your pain and sense that the doctor does not believe you. Maybe that physician, like me, has been burned.
We physicians should not allow a handful of deceitful patients to undermine our trust in the rest of the people we care for.
We patients, on the other hand, should recognize that some physicians view us with suspicion not because of anything we said or did, but because of other patients they have encountered, patients who left them feeling angry and embarrassed. We should hope that our physicians greet us with trusting attitudes. But we should not be surprised if building such trust takes time.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage
NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage

Yahoo

time9 hours ago

  • Yahoo

NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage

Over 340 current and recently terminated U.S. National Institutes of Health (NIH) employees have publicly protested the Trump administration's deep cuts to the agency's research budget. What Happened: Reuters noted that more than 60 NIH employees signed a letter, accusing NIH leadership — including Health Secretary Robert F. Kennedy — of allowing political interference to override scientific priorities. The stakes are high, they noted, citing how patient safety is at risk and public resources are wasted. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Signatories claim in the letter that the agency has eliminated 2,100 research grants worth $9.5 billion and cut another $2.6 billion in research contracts since Trump took office in January. The letter, also addressed to NIH Director Dr. Jay Bhattacharya and members of Congress, comes ahead of Bhattacharya's scheduled testimony before the Senate Appropriations Committee on Tuesday. The letter states that the cuts have halted clinical trials and left patients without oversight for experimental treatments or implanted devices. The employees told Reuters the terminated programs represented years of work and financial investment. They warned that the cuts were made without proper review, sometimes bypassing peer evaluations in favor of political It Matters: Bhattacharya said the letter mischaracterized NIH's recent policy directions. Citing internal staff reports, Reuters highlighted that the Trump administration has proposed slashing NIH's budget by $18 billion next year. This would reduce it by 40% to $27 billion. Nearly 5,000 NIH employees and contractors have already been laid off under Kennedy's restructuring of U.S. health agencies. In February, a complaint was filed arguing that 'Without relief from NIH's action, these institutions' cutting-edge work to cure and treat human disease will grind to a halt.' The lawsuit also mentioned, 'In issuing the Rate Change Notice, the NIH has also acted beyond its statutory authority and has failed to promulgate the change using notice and comment rulemaking.' In March, The U.S. Department of Health and Human Services (HHS) unveiled a sweeping restructuring plan to cut costs, streamline operations and refocus priorities. The restructuring will reduce the HHS workforce by 10,000 full-time employees, leading to annual savings of $1.8 billion. Through early retirements and other initiatives, the total number of employees will shrink from 82,000 to 62,000. Read Next: The average American couple has saved this much money for retirement — How do you compare? If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage originally appeared on

NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage
NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage

Yahoo

time9 hours ago

  • Yahoo

NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage

Over 340 current and recently terminated U.S. National Institutes of Health (NIH) employees have publicly protested the Trump administration's deep cuts to the agency's research budget. What Happened: Reuters noted that more than 60 NIH employees signed a letter, accusing NIH leadership — including Health Secretary Robert F. Kennedy — of allowing political interference to override scientific priorities. The stakes are high, they noted, citing how patient safety is at risk and public resources are wasted. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Signatories claim in the letter that the agency has eliminated 2,100 research grants worth $9.5 billion and cut another $2.6 billion in research contracts since Trump took office in January. The letter, also addressed to NIH Director Dr. Jay Bhattacharya and members of Congress, comes ahead of Bhattacharya's scheduled testimony before the Senate Appropriations Committee on Tuesday. The letter states that the cuts have halted clinical trials and left patients without oversight for experimental treatments or implanted devices. The employees told Reuters the terminated programs represented years of work and financial investment. They warned that the cuts were made without proper review, sometimes bypassing peer evaluations in favor of political It Matters: Bhattacharya said the letter mischaracterized NIH's recent policy directions. Citing internal staff reports, Reuters highlighted that the Trump administration has proposed slashing NIH's budget by $18 billion next year. This would reduce it by 40% to $27 billion. Nearly 5,000 NIH employees and contractors have already been laid off under Kennedy's restructuring of U.S. health agencies. In February, a complaint was filed arguing that 'Without relief from NIH's action, these institutions' cutting-edge work to cure and treat human disease will grind to a halt.' The lawsuit also mentioned, 'In issuing the Rate Change Notice, the NIH has also acted beyond its statutory authority and has failed to promulgate the change using notice and comment rulemaking.' In March, The U.S. Department of Health and Human Services (HHS) unveiled a sweeping restructuring plan to cut costs, streamline operations and refocus priorities. The restructuring will reduce the HHS workforce by 10,000 full-time employees, leading to annual savings of $1.8 billion. Through early retirements and other initiatives, the total number of employees will shrink from 82,000 to 62,000. Read Next: The average American couple has saved this much money for retirement — How do you compare? If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia

Yahoo

time2 days ago

  • Yahoo

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia. The FDA states that upon preliminary review, it found that the NDA was not sufficiently complete to permit a substantive review. Specifically, the FDA does not consider the second of the two placebo-controlled trials in the submission to be adequate and well-controlled because its primary endpoint was at 8 weeks and it used a flexible-dose paradigm. The FDA indicated that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled. The FDA did not raise any questions relating to the positive results of the studies, both of which met their primary endpoints. To address the FDA's feedback, Axsome will conduct an additional controlled trial, which will use a fixed-dose paradigm and a 12-week primary endpoint as requested by the FDA. Axsome anticipates initiating this trial in the fourth quarter of 2025. 'The clear feedback provided by the FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine allows us to move expeditiously with the continued development of this important investigational medicine for the approximately 17 million patients in the U.S. living with fibromyalgia. We are well positioned to initiate a new controlled trial that will incorporate the FDA's feedback by the end of 2025,' said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. 'As highlighted in the FDA's Patient-Focused Drug Development Initiative report The Voice of the Patient: Fibromyalgia, patients with fibromyalgia experience debilitating widespread pain, fatigue, and functional impairment, and report living with constant stigmatization, anxiety, depression, and fear of ongoing or worsening symptoms. We are excited and motivated by the potential for AXS-14 to address this high unmet medical need for patients, as evidenced by the consistent efficacy demonstrated to date across a broad range of fibromyalgia symptoms, including significant improvements in pain, function, and fatigue, in the completed trials.' About AXS-14 AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine. AXS-14 is an investigational drug product not approved by the FDA. About Fibromyalgia Fibromyalgia is a chronic debilitating disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.1 Other symptoms of this disorder can include tingling in the hands and feet and headaches.1 Fibromyalgia has considerable detrimental effects on physical, emotional, social, and day-to-day functioning.1 Fibromyalgia is considered to be mediated mainly in the central nervous system. Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from fibromyalgia.2 Treatment options for fibromyalgia are limited with only three pharmacologic treatments currently approved by the FDA. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are 'forward-looking statements'. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company's SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company's efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company's ability to maintain and expand payer coverage; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund the Company's disclosed clinical trials, which assumes no material changes to the Company's currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company's ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application ('NDA') for any of the Company's current product candidates; the Company's ability to fund additional clinical trials to continue the advancement of the Company's product candidates; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration ('FDA') or other regulatory authority approval of, or other action with respect to, the Company's product candidates, including statements regarding the timing of any NDA submission; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company's ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products and product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company's commercial launch of its other product candidates, if approved, and the potential impact on the Company's anticipated cash runway; the Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors:Mark JacobsonChief Operating Officer(212) 332-3243mjacobson@ Media:Darren OplandDirector, Corporate Communications(929) 837-1065dopland@ References: Matthew J. Bair, Erin E. Krebs. Fibromyalgia. Ann Intern Med. 2020;172:ITC33-ITC48. doi:10.7326/AITC202003030 Vincent A, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013 May;65(5):786-92. doi: 10.1002/ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store